JMIR Publications today released expert analysis of news and perspectives on the expansion of consumer wearable platforms into the clinical healthcare space. “The New Healthcare Gatekeeper: Introducing Wearables,” written by MedTech expert Blythe Karow, MBA, explains what it means for wearable technology companies to lead the initial conversations about patient health and the potential impact on patient trust, policy, and regulation.
own the first conversation
For decades, primary care physicians have served as the gateway to health care, organizing referrals, testing, and treatment, Karow writes. Currently, consumer wearable platforms are accumulating continuous physiological data such as sleep patterns, heart rate variability, and blood pressure trends, allowing users to detect changes in their health status. By incorporating artificial intelligence to interpret this data, these platforms effectively own the initial conversation about a patient’s health and are in a position to influence which specialists users see, which treatments they consider, and which care programs they enroll in.
Transition to clinical routing
Significant investments and strategic shifts demonstrate that wearables are no longer just an area of consumer technology. Carrow noted that fitness wristband company WHOOP recently closed a $575 million funding round with investments from Abbott and Mayo Clinic, and its newly formed affiliate was selected for Medicare’s outcomes-based chronic care model. Similar moves are occurring across the industry, with companies like Oura integrating with Medicare’s electronic health records infrastructure and companies like Apple, Samsung, and Verily building out clinical, regulatory, and reimbursement infrastructure. Wearables are now vying to become the routing layer of clinical care, relieving overworked physicians and assisting patients with proactive monitoring.
Addressing new regulatory risks
While there are clear benefits to continuous monitoring, Karow warns that the rapid integration of these platforms raises significant regulatory and ethical concerns. Consumer technology companies traditionally operate on business models built on user interest, subscription revenue, and monetizing user data. Unlike doctors in the United States, who are legally prohibited from reaping financial benefits when referring patients to certain specialists, wearable platforms that control physiological monitoring, AI interpretation, clinical routing, and reimbursement under one roof have yet to face similar structural antitrust scrutiny. The U.S. policy and regulatory framework is not yet ready to address the risks posed by the integration of consumer wearable platforms into healthcare, Carrow wrote. And so far, integration has not waited for policy to catch up.
sauce:
Reference magazines:
Karow, B., (2026) The new healthcare gatekeeper: Introducing wearables. Medical Internet Research Journal. DOI: 10.2196/101881. https://www.jmir.org/2026/1/e101881
